Copyright © 2004 by the European Society of Cardiology.
Clinical research
Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure
The Rotterdam Study
a Department of Epidemiology and Biostatistics, Erasmus Medical Centre, PO Box 1738, 3000, Rotterdam, The Netherlands
b Inspectorate for Healthcare, The Hague, The Netherlands
c Department of Cardiology, Erasmus Medical Centre, Rotterdam, The Netherlands
d Department of Medical Informatics, Erasmus Medical Centre, Rotterdam, The Netherlands
Received March 8, 2004; revised June 14, 2004; accepted June 24, 2004 * Corresponding author. Tel.: +31-10-4088294; fax: +31-10-4089382 (E-mail: b.stricker{at}erasmusmc.nl).
AIMS: To determine the prevalence, incidence rate, lifetime risk and prognosis of heart failure.
METHODS AND RESULTS: The Rotterdam Study is a prospective population-based cohort study in 7983 participants aged ⩾55. Heart failure was defined according to criteria of the European Society of Cardiology. Prevalence was higher in men and increased with age from 0.9% in subjects aged 55–64 to 17.4% in those aged ⩾85. Incidence rate of heart failure was 14.4/1000 person-years (95% CI 13.4–15.5) and was higher in men (17.6/1000 man-years, 95% CI 15.8–19.5) than in women (12.5/1000 woman-years, 95% CI 11.3–13.8). Incidence rate increased with age from 1.4/1000 person-years in those aged 55–59 to 47.4/1000 person-years in those aged ⩾90. Lifetime risk was 33% for men and 29% for women at the age of 55. Survival after incident heart failure was 86% at 30 days, 63% at 1 year, 51% at 2 years and 35% at 5 years of follow-up.
CONCLUSION: Prevalence and incidence rates of heart failure are high. In individuals aged 55, almost 1 in 3 will develop heart failure during their remaining lifespan. Heart failure continues to be a fatal disease, with only 35% surviving 5 years after the first diagnosis.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. van Noord, W. M van der Deure, M. C J M Sturkenboom, S. M J M Straus, A. Hofman, T. J Visser, J. A Kors, J. C M Witteman, and B. H C. Stricker High free thyroxine levels are associated with QTc prolongation in males J. Endocrinol., July 1, 2008; 198(1): 253 - 260. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. D. Schocken, E. J. Benjamin, G. C. Fonarow, H. M. Krumholz, D. Levy, G. A. Mensah, J. Narula, E. S. Shor, J. B. Young, and Y. Hong Prevention of Heart Failure: A Scientific Statement From the American Heart Association Councils on Epidemiology and Prevention, Clinical Cardiology, Cardiovascular Nursing, and High Blood Pressure Research; Quality of Care and Outcomes Research Interdisciplinary Working Group; and Functional Genomics and Translational Biology Interdisciplinary Working Group Circulation, May 13, 2008; 117(19): 2544 - 2565. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Konhilas and L. A. Leinwand The Effects of Biological Sex and Diet on the Development of Heart Failure Circulation, December 4, 2007; 116(23): 2747 - 2759. [Full Text] [PDF]
|
|
|
|
 |
|
 L. Selman, R. Harding, T. Beynon, F. Hodson, E. Coady, C. Hazeldine, M. Walton, L. Gibbs, and I. J Higginson Improving end-of-life care for patients with chronic heart failure: "Let's hope it'll get better, when I know in my heart of hearts it won't" Heart, August 1, 2007; 93(8): 963 - 967. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A.-J. L.H.J. Aarnoudse, C. Newton-Cheh, P. I.W. de Bakker, S. M.J.M. Straus, J. A. Kors, A. Hofman, A. G. Uitterlinden, J. C.M. Witteman, and B. H.C. Stricker Common NOS1AP Variants Are Associated With a Prolonged QTc Interval in the Rotterdam Study Circulation, July 3, 2007; 116(1): 10 - 16. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Selman, R. Harding, T. Beynon, F. Hodson, C. Hazeldine, E. Coady, L. Gibbs, and I. J. Higginson Modelling services to meet the palliative care needs of chronic heart failure patients and their families: current practice in the UK Palliative Medicine, July 1, 2007; 21(5): 385 - 390. [Abstract] [PDF]
|
|
|
|
|
|
P. W F B.-A. de la Porte, D. J A Lok, D. J van Veldhuisen, J. van Wijngaarden, J. H Cornel, N. P A Zuithoff, E. Badings, and A. W Hoes Added value of a physician-and-nurse-directed heart failure clinic: results from the Deventer-Alkmaar heart failure study Heart, July 1, 2007; 93(7): 819 - 825. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Caples and V. K. Somers CPAP treatment for obstructive sleep apnoea in heart failure: expectations unmet Eur. Heart J., May 2, 2007; 28(10): 1184 - 1186. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Herrmann, S. Muller, I. Kindermann, L. Gunther, J. Konig, M. Bohm, and W. Herrmann Plasma B vitamins and their relation to the severity of chronic heart failure Am. J. Clinical Nutrition, January 1, 2007; 85(1): 117 - 123. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. C. van Vark, I. Kardys, G. S. Bleumink, A. M. Knetsch, J. W. Deckers, A. Hofman, B. H.Ch. Stricker, and J. C.M. Witteman Lipoprotein-associated phospholipase A2 activity and risk of heart failure: the Rotterdam Study Eur. Heart J., October 1, 2006; 27(19): 2346 - 2352. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. R. van Kimmenade, J. L. Januzzi Jr, P. T. Ellinor, U. C. Sharma, J. A. Bakker, A. F. Low, A. Martinez, H. J. Crijns, C. A. MacRae, P. P. Menheere, et al. Utility of Amino-Terminal Pro-Brain Natriuretic Peptide, Galectin-3, and Apelin for the Evaluation of Patients With Acute Heart Failure J. Am. Coll. Cardiol., September 19, 2006; 48(6): 1217 - 1224. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. P. Dembitsky REMATCH and Beyond: The Cost of Treating Heart Failure Using an Implantable Left Ventricular Assist Device. Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 2006; 10(3): 253 - 255. [Abstract] [PDF]
|
|
|
|
 |
|
 A. Nair, B. Sealove, J. L. Halperin, G. Webber, and V. Fuster Anticoagulation in patients with heart failure: who, when, and why? Eur. Heart J. Suppl., September 1, 2006; 8(suppl_E): E32 - E38. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J.V. McMurray, F. L. Andersson, S. Stewart, K. Svensson, A. C. Solal, R. Dietz, J. Vanhaecke, D. J. van Veldhuisen, J. Ostergren, C. B. Granger, et al. Resource utilization and costs in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur. Heart J., June 1, 2006; 27(12): 1447 - 1458. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. S. van der Hooft, J. Heeringa, G. G. Brusselle, A. Hofman, J. C. M. Witteman, J. H. Kingma, M. C. J. M. Sturkenboom, and B. H. Ch. Stricker Corticosteroids and the risk of atrial fibrillation. Arch Intern Med, May 8, 2006; 166(9): 1016 - 1020. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Heeringa, D. A.M. van der Kuip, A. Hofman, J. A. Kors, G. van Herpen, B. H.Ch. Stricker, T. Stijnen, G. Y.H. Lip, and J. C.M. Witteman Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study Eur. Heart J., April 2, 2006; 27(8): 949 - 953. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. S Schleithoff, A. Zittermann, G. Tenderich, H. K Berthold, P. Stehle, and R. Koerfer Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. Am. J. Clinical Nutrition, April 1, 2006; 83(4): 754 - 759. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M.J.M. Straus, J. A. Kors, M. L. De Bruin, C. S. van der Hooft, A. Hofman, J. Heeringa, J. W. Deckers, J. H. Kingma, M. C.J.M. Sturkenboom, B. H. Ch. Stricker, et al. Prolonged QTc Interval and Risk of Sudden Cardiac Death in a Population of Older Adults J. Am. Coll. Cardiol., January 17, 2006; 47(2): 362 - 367. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Dickstein C-reactive protein in ischaemic cardiomyopathy: assessing vascular risk in heart failure Eur. Heart J., November 1, 2005; 26(21): 2218 - 2219. [Full Text] [PDF]
|
|
|
|
 |
|
 W. C. Stanley, F. A. Recchia, and G. D. Lopaschuk Myocardial Substrate Metabolism in the Normal and Failing Heart Physiol Rev, July 1, 2005; 85(3): 1093 - 1129. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Erdmann The Benefits of Angiotensin Receptor Blockers in Patients with Chronic Heart Failure and Multiple Co-morbidities Journal of Renin-Angiotensin-Aldosterone System, June 1, 2005; 6(2_suppl): S11 - S12. [Abstract] [PDF]
|
|
|
|
|
|
H.-H. S. Oei, I. M. van der Meer, A. Hofman, P. J. Koudstaal, T. Stijnen, M. M.B. Breteler, and J. C.M. Witteman Lipoprotein-Associated Phospholipase A2 Activity Is Associated With Risk of Coronary Heart Disease and Ischemic Stroke: The Rotterdam Study Circulation, February 8, 2005; 111(5): 570 - 575. [Abstract] [Full Text] [PDF]
|
|